Clinical trials: Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS
At present, the main therapies for myelodysplastic syndromes with ring sideroblasts (MDS-RS) are red blood cell and platelet transfusion, erythropoietin (EPO), androgen, and iron chelation therapy.
- Trial name
- NCT06004765
- Testing
- Lenalidomide, Azacitidine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Peking Union Medical College Hospital
Hematologic Malignancy, GvHD
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell…
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
- Trial name
- NCT06462365
- Testing
- TRX103
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tr1X, Inc.
Neoplasms, Lymphomas
Collection of Tissue Samples for Cancer Research
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.
- Conditions
- Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00900198
- Testing
- Biopsy
- Where
- 17 sites in United States, Canada
- Volunteers
- 5,000 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Leukemia
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
In this study two cord blood collections will be used to increase the number of cord blood cells you will receive on transplant day. We call this a "double unit" cord blood transplant.
- Conditions
- Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT00597519
- Testing
- Fludarabine, Cyclophosphamide, Transplantation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Paroxysmal Nocturnal Hemoglobinuria
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in participants with PNH.
- Trial name
- NCT06100900
- Testing
- BCX10013
- Where
- 4 sites in Malaysia, South Africa
- Volunteers
- 8 people
- Sponsor
- BioCryst Pharmaceuticals
Paroxysmal Hemoglobinuria, Nocturnal
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
This study will evaluate the safety and effectiveness of the experimental drug eculizumab for treating paroxysmal nocturnal hemoglobinuria (PNH), a disorder that can cause premature destruction of red blood cells.
- Trial name
- NCT00130000
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematologic Malignancies
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or…
- Trial name
- HPDSC (NCT00596999)
- Testing
- UCB and HPDSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00689000
- Testing
- CHR-2797 (tosedostat): Aminopeptidase inhibitor
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chroma Therapeutics
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
This clinical trial uses a laboratory test called a high throughput sensitivity assay in planning treatment for patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01872819
- Testing
- antitumor drug screening assay, chemotherapy, biological therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington
Leukemia, Myelodysplastic Syndromes
Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of sodium salicylate in treating patients who have…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00004245
- Testing
- sodium salicylate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
Experimental Bone Marrow Transplant Protocol
Bone marrow transplantation (BMT) is a risky procedure. If doctors could reduce the complications, BMT would be safer to use for a wider range of conditions.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00061581
- Testing
- Isolex 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelodysplastic Syndromes
Ascorbate in Myelodysplastic Syndrome
This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
- Trial name
- AIMS (NCT07283900)
- Testing
- High-dose ascorbate, Azacitidine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Prajwal Dhakal
Acute Myeloid Leukemia, Myelodysplastic Syndromes
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.
- Trial name
- NCT04263181
- Testing
- Peripheral blood draw, Bone marrow aspirate, Buccal swab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Washington University School of Medicine
Leukemia, Myelodysplastic Syndromes
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer.
- Trial name
- NCT00516828
- Testing
- cytarabine
- Where
- 4 sites in Canada
- Volunteers
- 21 people
- Sponsor
- NCIC Clinical Trials Group
Acute Leukemia, Chronic Myelogenous Leukemia
Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation
350 patients with early leukemias were assigned to receive peripheral blood or bone marrow transplantation; the occurrence of acute and chronic graft versus host disease, survival, transplantation-related mortality, and relapse…
- Conditions
- Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01020175
- Testing
- Bone marrow transplantation, Peripheral blood stem cell transplantation
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Stem Cell Transplant Complications, Graft Vs Host Disease
IS-free Treg HaploHCT
This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or…
- Conditions
- Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder)
- Trial name
- NCT04678401
- Testing
- Radiation, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia
- Trial name
- NCT00963495
- Testing
- Clioquinol
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Myelodysplastic Syndromes
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in low- and intermediate-risk myelodysplastic syndrome (MDS) patients who receive haploidentical hematopoietic stem cell transplantation…
- Trial name
- NCT03412266
- Testing
- Cytarabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Solid Tumors, Acute Myeloid Leukemia
A Study of PLX51107 in Advanced Malignancies
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced…
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02683395
- Testing
- PLX51107
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Plexxikon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.